US Begins Clinical Trials On Genital Herpes Vaccine

Nov 9, 2013
Random Adult News
0 0

BETHESDA, Md., Nov. 8 (UPI) — U.S. researchers began an early stage clinical trial of a vaccine to prevent genital herpes disease by removing two key proteins so the virus cannot multiply.

Principal investigator Dr. Lesia K. Dropulic of the National Institute of Allergy and Infectious Disease’s Laboratory of Infectious Diseases said the trial will test an investigational herpes simplex virus type 2 vaccine candidate, called HSV529, for safety and the ability to generate an immune system response. The Phase I trial is being conducted at the National Institute of Health’s Clinical Center in Bethesda, Md.

The investigational vaccine was manufactured by Sanofi Pasteur and developed by David Knipe, a professor of microbiology and immunobiology at Harvard Medical School in Boston. Preclinical testing of the candidate vaccine involved a 10-year collaborative effort between Knipe Dr. Jeffrey Cohen, chief of NIAID’s Laboratory of Infectious Diseases.

Genital herpes is one of the most common sexually transmitted infections in the United States and while genital herpes is caused by herpes simplex virus type 2, herpes simplex virus type 1 can also cause genital herpes.

10-year effort to create vaccine to prevent genital herpes tested. National Institute of Allergy and Infectious Diseases Director Anthony Fauci. UPI/Roger L. Wollenberg.

10-year effort to create vaccine to prevent genital herpes tested. National Institute of Allergy and Infectious Diseases Director Anthony Fauci. UPI/Roger L. Wollenberg.

“Although genital herpes is treatable, it is a lifelong infection that can exact a substantial psychological and physical toll on infected individuals and places them at higher risk of acquiring HIV,” Dr. Anthony S. Fauci, director of the NIAID, said in a statement.

“Furthermore, mothers with active genital herpes infection at time of delivery can transmit the virus to their newborns, which can lead to severe illness and death. A protective vaccine would help to reduce significantly the spread of this all-too-common sexually transmitted infection.”

An estimated 776,000 people in the United States are infected with herpes simplex virus type 2 or herpes simplex virus type 1 each year.

© 2013 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.

Source

0 0 vote
Article Rating
Spread the love
Comments
Subscribe
Notify of
guest

This site uses Akismet to reduce spam. Learn how your comment data is processed.

1 Comment
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
crunkleshcwitz
crunkleshcwitz
6 years ago

Dude, if they can get a vaccine for herpes and that foot cream to kill HIV, I’m definitely gonna get snipped at 40 and go full time bare back. My morning after pill will be Amoxicillin.

TrafficHolder.com - Buy & Sell Adult Traffic
1
0
Would love your thoughts, please comment.x
()
x